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ABSTRACT
Objective: Our goal was to determine the in vitro susceptibility of Ureaplasma urealyticurn and
Mycoplasma korninis isolates to several antibiotics in Argentina.
Metkods: Ninety-four strains of U. urealyticum and 18 strains of M. korninis isolated from cervical
and urethral specimens were studied. Broth microdilution and agar dilution tests for minocycline,
tetracycline, erythromycin, ciprofloxacin, and ofloxacin were performed.
Results: Both methods proved to be reliable and reproducible for U. urealyticum and M. kominis,
with no major differences in results. The U. urealyticurn strains were inhibited by erythromycin at
MICs ranging from <-0.5 to >8 g/ml. Ofloxacin showed the highest activity against this latter
organism. No differences between tetracycline and minocycline MICs were observed with U.
urealyticum. Two M. kominis strains displaying high MICs both to tetracycline and to minocycline
were detected.
Conclusions: The emerging resistance ofmycoplasmas to certain antibiotics emphasizes the need
to undertake further surveillance studies on the clinical isolates of such organisms.
(C) 1996 Wiley-Liss, Inc.
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he antimicrobial susceptibility of the 2 most
common genital mycoplasmas, Ureaplasma ure-
alyticum and Mycoplasma hominis, is of interest be-
cause they have been recognized as pathogens in
infections of the newborn, 1,e arthritis, and particu-
larly sexually transmitted diseases (STDs) such as
urethritis3’4 and pelvic inflammatory disease. 3,4
Since resistance to traditional drugs, such as tet-
racycline, used for treating these infections is
widely known for both U. urealyticum and M. hom-
inis,
s-9 alternative antimicrobial agents should be
evaluated.
The purpose of the present study was to deter-
mine the susceptibility of clinical isolates of U. ure-
alyticum and M. hominis to 5 antibiotics and compare
the results obtained from agar dilution and broth
microdilution tests.
MATERIALS AND METHODS
Ninety-five isolates of U. urealjticum and 19 of el/.
aominis strains were tested. The U. urealyticum iso-
lates included reference strain (Mycotrin system)
and 94 low-passage clinical isolates from the cervix,
urethra, sperm, or first-catch urine. The el//. aominis
isolates included 1 M. aominis reference strain (PG
21) obtained from the U.S. National Institutes of
Health and 18 low-passage clinical isolates from the
cervix, urethra, or sperm. All clinical isolates were
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collected and identified from 1990 to 1992 and
stored at -70C until used.
U. urealyticum was identified by urease produc-
tion in U9 broth1 and typical colonies in Ureaplasma
differential agar medium (A7). 1’11 M. hominis was
identified by arginine hydrolysis, typical colonies
in Hayflick modified-agar medium,
1 and growth
inhibition by M. hominis antiserum (provided by
David Rose).z
Antimicrobial Agents
The reference standard powers for in vitro suscepti-
bility testing ofminocycline (Lederle Laboratories),
tetracycline hydrochloride (Pfizer Laboratories,
Groton, CT), erythromycin base (Leptit Labora-
tories), ciprofloxacin (Syntial Laboratories), and
ofloxacin (Cilag Laboratories) were obtained from
the manufacturers. All 5 were used for U. urealyti-
cure, but erythromycin was excluded for M. hominis
because of its natural resistance.
Inoculum
Aliquots of stock culture were frozen at -70C and
6 10-fold serial dilutions in U9 broth (pH 6.0) for
ureaplasmas or arginine broth (pH 7.0)
3 for myco-
plasmas were prepared in order to determine the
number of color-changing units (ccu) present (0.1
ml of organism suspension/0.9 ml of broth). A ccu
was designated as the reciprocal of the highest dilu-
tion at which growth was present, as evidenced by
an alkaline shift in the phenol red pH indicator. The
stock cultures were thawed to room temperature on
the day of the assay and diluted in the appropriate
broth without antibiotics to reach the 104-105 ccu/
ml range.
4 The inoculum size was checked at the
time of the assay, and the organism suspensions
were "activated" by 2-h incubation prior to inoculat-
ing the test media.
Broth Microdilution Test
U9 broth (pH 6.0) and arginine broth (pH 7.0) were
used for testing U. urealyticum and M. hominis, re-
spectively.
4-16 Broth volumes of 100 lxl were inocu-
lated into each well of 96-well microtiter plates. A
100-1,1 antibiotic stock solution was added to the
first well and serial 2-fold dilutions to the remaining
wells in each row were inoculated with 100 I,1 of
either organism inoculum until the final antibiotic
concentration reached a range of 16-0.5 pg/ml. Sep-
arately, the wells without drugs containing serial
10-fold organism dilutions were used as a positive
growth control, while the wells lacking organisms
and drug were used as a sterility control. Microtiter
plates were sealed and incubated for 48 h in an
ambient atmosphere at 35C. The plates were ob-
served for evidence of growth (color change). The
MIC was defined as the lowest antibiotic concentra-
tion at which the color remained unaltered (no
growth), as compared with the control growth color
change. All assays were performed twice on differ-
ent days.
Agar Dilution Test
Ureaplasma differential agar medium (A7) and
Hayflick modified-agar medium (Hm) were used
for testing U. urealyticum and M. hominis, respec-
tively. 17 One milliliter of 2-fold serial antibiotic dilu-
tion was added to 9 ml of agar medium, to reach a
final range of 16-0.5 Ixg/ml. For U. urealyticum and
M. hominis, a 10 ccu/ml was placed into each well
of a Steers replicator and inoculated on Hm and A7
agar, reaching 104 organism/spot. The plates with-
out antibiotics were used as a positive growth con-
trol. All plates were incubated in an ambient atmo-
sphere with 5% COz for 48 h at 35C and were
viewed with a microscope at 25 and 100 magnifi-
cations. The MIC was defined as the lowest antimi-
crobial concentration in which no growth (no col-
ony) was observed compared with the growth
control plate.
SusceptibiliW Test Control
Staphylococcus aureus ATCC 25923 was used as a
control for potential interaction of antibiotics, me-
dium components, and pH influence. This strain
was tested by broth microdilution and agar dilution
tests. The MICs of S. aureus ATCC 25923 were
simultaneously performed in Muller-Hinton agar
and Muller-Hinton broth by the microdilution
method. This control was performed twice on 2
different days.
RESULTS
The broth microdilution and agar dilution tests
proved to be reliable and reproducible for U. urealy-
ticum and M. hominis, with no major differences be-
tween the methods.
Table shows the MIC results and resistance
rates by both methods for 5 antibiotics against U.
urealyticum. The erythromycin inhibition and MIC
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TABLE I. MICs of 5 antibiotics for 94 U. urealyticum strains by 2 different methods
Method
Broth microdilution Agar dilution
Antibiotic MICs0 MIC90 Range % R MICs0 MICg0 Range % R
Minocycline -<0.5 -<0.50-> 16 5 -<0.5 2
Tetracycline -<0.5 2 -<0.50-> 16 5.5 -<0.5 2
Erythromyc n 2 4 -<0.50->8 0.5 2
Ciprofloxacin 2 2 -<0.50->8 9.5 2 2
Ofloxacin -<0.50-2 0 0.5
-<0.50-> 16
-<0.50-> 16
-<0.50->8
-<0.50->8
-<0.50-2
4
3.5
9.5
0
aMIC and range are given as Ig/ml. R, resistance.
TABLE 2. MICs of 4 antibiotics for 18 M. hominis strains by 2 different methods
Metho&
Broth microdilution Agar dilution
Antibiotic MICs0 MIC90 Range % R MICs0 MIC90 Range % R
Minocycline -<0.5 -<0.5 -<0.50-> 16 -<0.5
Tetracycline -<0.5 -<0.5 -<0.50-> 16 -<0.5
Ciprofloxacin -<0.5 -<0.50-I 0 -<0.5
Ofloxacin -<0.5 -<0.5 -<0.50-I 0 -<0.5
-<0.5 -<0.50-> 16
2 -<0.50-> 16
-<0.50-2 0
2 -<0.50-2 0
aMIC and range are given as Ig/ml. R, resistance.
50% and 90% were slightly higher by the broth
microdilution vs. the agar dilution test. Only
erythromycin-resistant strain was detected. Both
methods yielded similar MIC 50%, MIC 90%, and
resistance rates for all antibiotics, except that 1
strain showed resistance to minocycline by the
broth microdilution test, but not by the agar dilution
test. Ofloxacin was the most active antibiotic tested
against U. urealyticum, whereas ciprofloxacin was
somewhat less active (9.5% resistance).
The MICs and resistance rates for 4 antibiotics
against M. hominis are given in Table 2. By both
methods, 2 strains displayed high minocycline or
tetracycline MICs, i.e., > 16 lg/ml, 11% resistance.
No differences between ofloxacin and ciprofloxacin
MICs were observed, even for strains showing ei-
ther high or low tetracycline MICs.
No major differences were found in the MICs
of the 5 antibiotics against S. aureus ATCC 25293
control in U9 broth, A7 agar, or Hayflick agar. The
MIC values were within the acceptable range es-
tablished for Muller-Hinton broth and Muller-
Hinton agar.
18
DISCUSSION
The wide spectrum of mycoplasma susceptibility
tests so far described has been restricted to differ-
ences in technique, inoculum size, pH media, incu-
bation conditions, and endpoint criteria. 5’16’19 The
medium used for U. urealyticum and M. hominis is
complex, containing 10-20% serum, which makes
the MIC values more difficult to compare with
those from other bacteria that grow in simple me-
dium. It has been speculated that the complex me-
dia and conditions necessary for optimal culture
and susceptibility testing ofmycoplasmas may exert
some effect on the activity or stability of various
antimicrobial agents. Robertson et al. 15 failed to
find any apparent binding effect when testing the
susceptibility of U. urealyticum strains against tetra-
cycline, erythromycin, and rosaramicin, but the ex-
pected decrease in macrolide activity at pH 6.0
was observed.
Since mycoplasmas exhibit no turbidity as evi-
dence of growth and both M. hominis and U. urealyti-
cure die soon after reaching peak growth, the prepa-
ration of suitable inocula is more difficult than with
common bacteria. Using inocula higher than recom-
mended, the MICs frequently were raised over
2-fold. 14’17 Until standardized methods to test my-
coplasma susceptibility are available, these incon-
sistencies will continue.
Comparing the results obtained with broth mi-
238 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYANTIMICROBIAL AGENTS VS. MYCOPLASMAS SMAYEVSKYET AL.
crodilution and agar dilution tests, we found no
significant differences, as reported by Cummings
and McCormack.
In agreement with Robertson et al.,
15 the broth
microdilution test seemed a simple and sensitive
growth indicator.
Kenny et al. 17 contended that the agar dilution
method was more useful, as it was able to detect
mixtures of susceptible and resistant mycoplasmas
as well as spontaneous resistant mutants. Further-
more, the agar dilution test affords the advantage
of testing many strains at one time.
The prevalence of U. urealyticum strains dis-
playing high MICs to erythromycin found in this
study was lower than that described by other au-
thors. 15,6 However, Waites et al. reported a rela-
tively narrow MIC range (0.25-4 Ig/1) when testing
U. urealyticum erythromycin resistance.
The 6-fluoroquinolones offer a useful alternative
for the treatment of infections caused by gonococci
and other genital pathogens that are resistant to
penicillin and tetracycline. These quinolones are
remarkable for being able to inhibit both 3/1. hominis
and U. urealyticum at MIC levels attainable in tissue.
In our study, ofloxacin proved more active than
ciprofloxacin against U. urealyticum, as reported by
Kenny et al.7 Likewise, we failed to detect any M.
hominis strains that were resistant to either ciproflox-
acin or ofloxacin, which was in agreement with
other authors.9,7’9
Cummings and McCormack reported that M.
hominis isolates in the northeastern United States
have become more resistant to tetracycline and mi-
nocycline during the past decade, but data available
in Argentina are insufficient to anticipate a simi-
lar trend.
The low levels of clinical resistance obviously
conflict with the outcome of therapy predicted from
MIC or serum levels. Since few U. urealyticum and
M. hominis infections are septiccmias, the achiev-
able serum drug level may not reflect its concentra-
tion at the actual site of infection. Therefore, serum
levels exceeding the MIC may be required for a
bacteriologic cure.
In conclusion, the emerging resistance of myco-
plasmas to certain antibiotics emphasizes the need
to undertake further surveillance studies on the
clinical isolates of such organisms. Furthermore, in
addition to in vitro susceptibility and pharmacoki-
netic studies, clinical trials including suitable antibi-
otics to be used in mycoplasmal or unreaplasmal
infections are essential before extrapolating in vitro
findings to human treatment.
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